🧠 At a glance:
Suraksha Diagnostic Ltd (CMP ₹336.55) reported a 34% jump in PAT for FY25, driven by a 15% revenue increase and stable EBITDA margins at 34%. But the real story? Their post-IPO debut year included an aggressive genomics entry via Fetomat acquisition, new center expansions, and resilience despite doctor strikes and international hiccups. Is this Kolkata-based diagnostic juggernaut quietly gearing up for a national-level play?
🔖 Title Tag:
Suraksha Diagnostic FY25 Results: 34% PAT Jump, Fetomat Genomic Push, Expansion Plan FY26
🧾 Meta Description:
Suraksha Diagnostic posted 34% PAT growth in FY25 with strong EBITDA. Read about their genomic medicine entry, expansion plans, and if this East India giant is ready to go national.
🧬 About the Company:
- Name: Suraksha Diagnostic Limited
- Headquarters: Kolkata, West Bengal
- Sector: Healthcare – Diagnostics (Pathology, Radiology, Consultations)
- Presence: West Bengal, Bihar, Assam, Meghalaya
- Network: NABL & NABH accredited labs, 7 new centers added in FY25
- Recent IPO: FY24
- New Business Angle: Genomic diagnostics via acquisition of Fetomat Wellness Pvt Ltd
🧑⚕️ Key Managerial Personnel (KMP):
- Ms. Ritu Mittal – Joint Managing Director & CEO
- Mamta Jain – Company
